AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10087080 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses of faster responders
Number of subjects: 10
Study 10087080 — intervention group
Group type: EXPERIMENTAL
Intervention: Responses of slower responders
Number of subjects: 10
Study 7499063 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP infusion
Number of subjects: 16
Study 1524277 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg single dose
Number of subjects: 12
Study 1524277 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg single dose
Number of subjects: 12
Study 1524277 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg b.i.d. at steady state
Number of subjects: 12
Study 1524277 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg b.i.d.
Number of subjects: 12
Study 1524277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6350072 — intervention group
Group type: EXPERIMENTAL
Intervention: Tioconazole base 1% cream applied twice daily
Number of subjects: 61
Study 6350072 — intervention group
Group type: COMPARATOR
Intervention: Econazole nitrate 1% cream applied twice daily
Number of subjects: 61
Study 31206782 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame intervention
Number of subjects: 55
Study 30323575 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 74
Study 30323575 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapeutic intervention)
Number of subjects: 74
Study 26739729 — intervention group
Group type: EXPERIMENTAL
Intervention: Participative learning intervention
Number of subjects: 1494
Study 26739729 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-mentoring intervention
Number of subjects: 1494
Study 26739729 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (peer-mentoring + participative learning)
Number of subjects: 1494
Study 26739729 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1494
Study 24384865 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration with oral rehydration solution (ORS), average consumption of 2040 mL (range; 1800-2500 mL)
Number of subjects: 5
Study 24384865 — intervention group
Group type: COMPARATOR
Intervention: Dehydration
Number of subjects: 5
Study 22375612 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide twice daily plus sitagliptin and metformin (ADD group)
Number of subjects: 255
Study 22375612 — intervention group
Group type: COMPARATOR
Intervention: Exenatide twice daily plus placebo and metformin (SWITCH group)
Number of subjects: 255
Study 20569728 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BIV) antitachycardia pacing (ATP)
Number of subjects: 526
Study 20569728 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular (RV) antitachycardia pacing (ATP)
Number of subjects: 526
Study 16480973 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher perceptual load (increased numbers of search items or a harder discrimination vs. detection task)
Number of subjects: 0
Study 16480973 — intervention group
Group type: COMPARATOR
Intervention: Lower perceptual load (not explicitly defined in the abstract)
Number of subjects: 0
Study 15961357 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg (TPTD20)
Number of subjects: 801
Study 15961357 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 801
Study 12168123 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure support ventilation with volume guarantee (PSV+VG)
Number of subjects: 14
Study 12168123 — intervention group
Group type: COMPARATOR
Intervention: Synchronized intermittent mandatory ventilation (SIMV)
Number of subjects: 14
Study 10435066 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol therapy (2 mg/day)
Number of subjects: 25
Study 10435066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7501671 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg caffeine
Number of subjects: 0
Study 7501671 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg caffeine
Number of subjects: 0
Study 7501671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2182444 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 Gy cranial irradiation
Number of subjects: 1165
Study 2182444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-dose i.v. methotrexate (ID-MTX) (4 x 0.5 g/m2)
Number of subjects: 1165
Study 2182444 — intervention group
Group type: COMPARATOR
Intervention: No irradiation
Number of subjects: 1165
Study 2182444 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 Gy or 18 Gy cranial irradiation
Number of subjects: 1165
Study 2182444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive reinduction regimen (protocol III)
Number of subjects: 1165
Study 2182444 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 1165
Study 7028208 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 221
Study 7028208 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 31601514 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/d
Number of subjects: 1110
Study 31601514 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib 50 mg/d, 4 weeks on/2 weeks off
Number of subjects: 1110
Study 31601514 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/d without AE-related dose reductions
Number of subjects: 1110
Study 31601514 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg/d with AE-related dose reductions
Number of subjects: 1110
Study 31601514 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib 50 mg/d without AE-related dose reductions
Number of subjects: 1110
Study 31601514 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib 50 mg/d with AE-related dose reductions
Number of subjects: 1110
Study 28935273 — intervention group
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol (EP) administered every 21 days (q21d)
Number of subjects: 139
Study 28935273 — intervention group
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol (EP)
Number of subjects: 139
Study 26827187 — intervention group
Group type: EXPERIMENTAL
Intervention: Real 1.0 mA tDCS over sensory cortex for 20 min
Number of subjects: 60
Study 26827187 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 60
Study 24846279 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of K18 in adults with histologic improvement at week 96
Number of subjects: 383
Study 24846279 — intervention group
Group type: COMPARATOR
Intervention: Serum levels of K18 in adults without histologic improvement
Number of subjects: 383
Study 24846279 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of K18 in children with histologic improvements at week 48
Number of subjects: 383
Study 24846279 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of K18 in children with histologic improvements at week 96
Number of subjects: 383
Study 24846279 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of K18 in adults
Number of subjects: 383
Study 24846279 — intervention group
Group type: COMPARATOR
Intervention: Alanine aminotransferase levels in adults
Number of subjects: 383
Study 24846279 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of K18 in children
Number of subjects: 383
Study 24846279 — intervention group
Group type: COMPARATOR
Intervention: Alanine aminotransferase levels in children
Number of subjects: 383
Study 22487036 — intervention group
Group type: EXPERIMENTAL
Intervention: Long decision time condition
Number of subjects: 0
Study 22487036 — intervention group
Group type: COMPARATOR
Intervention: Short decision time condition
Number of subjects: 0
Study 19543499 — intervention group
Group type: EXPERIMENTAL
Intervention: Rush immunotherapy (RIT) with Dermatophagoides farinae (Der f) and Dermatophagoides pteronyssinus (Der p)
Number of subjects: 15
Study 19543499 — intervention group
Group type: COMPARATOR
Intervention: Control group (no RIT)
Number of subjects: 15
Study 17292595 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ‐114 (Saireito) at a dose of 9 g/day for 2 days before surgery and for 2 weeks after surgery
Number of subjects: 17
Study 17292595 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ‐114 (Saireito)
Number of subjects: 17
Study 17292595 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TJ‐114)
Number of subjects: 17
Study 15308514 — intervention group
Group type: COMPARATOR
Intervention: CT guided suprascapular nerve block with methylprednisolone acetate and bupivacaine
Number of subjects: 67
Study 15308514 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical landmark approach suprascapular nerve block
Number of subjects: 67
Study 11354593 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving remediation (10 sessions)
Number of subjects: 54
Study 11354593 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training (10 sessions)
Number of subjects: 54
Study 11354593 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 9742275 — intervention group
Group type: EXPERIMENTAL
Intervention: d,l-methadone
Number of subjects: 40
Study 9742275 — intervention group
Group type: COMPARATOR
Intervention: l-methadone
Number of subjects: 40
Study 8113113 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate suspension
Number of subjects: 0
Study 8113113 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 3289768 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural analgesia (Group A)
Number of subjects: 60
Study 3289768 — intervention group
Group type: COMPARATOR
Intervention: Intermittent epidural analgesia (Group B)
Number of subjects: 60
Study 3289768 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 29944651 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose oral ciprofloxacin for household contacts within 24 hours of case notification
Number of subjects: 49
Study 29944651 — intervention group
Group type: EXPERIMENTAL
Intervention: Village-wide distribution of ciprofloxacin within 72 hours of first case notification
Number of subjects: 49
Study 29944651 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 49
Study 28780509 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention
Number of subjects: 1137
Study 26020438 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-radiation-dose CT images scored by eight radiologists using morphologic categories proposed by the Fleischner Society guidelines.
Number of subjects: 160
Study 26020438 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodule categorization as part‐solid nodules and location in the upper lobe.
Number of subjects: 160
Study 26020438 — intervention group
Group type: EXPERIMENTAL
Intervention: All possible reading pairs (28 possible combinations of observer pairs x 160 nodules = 4480 possible agreements or disagreements).
Number of subjects: 160
Study 26020438 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrepant readings of nodule classification.
Number of subjects: 160
Study 23358975 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem‐solving skills training (PSST)
Number of subjects: 309
Study 23358975 — intervention group
Group type: COMPARATOR
Intervention: Nondirective support (NDS)
Number of subjects: 309
Study 21362684 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing oocyte collection when the leading follicle had a diameter of 22 mm
Number of subjects: 190
Study 19170143 — intervention group
Group type: EXPERIMENTAL
Intervention: C. colocynthis fruit capsules (100 mg, three times a day)
Number of subjects: 50
Study 19170143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16824998 — intervention group
Group type: EXPERIMENTAL
Intervention: RT3DE with contrast enhancement
Number of subjects: 24
Study 16824998 — intervention group
Group type: COMPARATOR
Intervention: RT3DE without contrast
Number of subjects: 24
Study 16824998 — intervention group
Group type: EXPERIMENTAL
Intervention: RT3DE with good endocardial definition
Number of subjects: 24
Study 12895212 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-H. pylori therapy
Number of subjects: 24
Study 12895212 — intervention group
Group type: COMPARATOR
Intervention: H. pylori negative status
Number of subjects: 24
Study 10705200 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB) with goserelin acetate 3.6 mg and flutamide 250 mg three times daily
Number of subjects: 589
Study 10705200 — intervention group
Group type: COMPARATOR
Intervention: Goserelin acetate 3.6 mg alone
Number of subjects: 589
Study 10705200 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB)
Number of subjects: 589
Study 9161864 — intervention group
Group type: EXPERIMENTAL
Intervention: Tsumura Chorei‐to
Number of subjects: 74
Study 9161864 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 74
Study 8477016 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 30
Study 8477016 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 30
Study 3530176 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (VCR, NMM, Act.‐D)
Number of subjects: 92
Study 3530176 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (VCR, NMM, Act.‐D, DTIC)
Number of subjects: 92
Study 3530176 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (VCR, Act.‐D, CCNU, DTIC)
Number of subjects: 92
Study 3530176 — intervention group
Group type: COMPARATOR
Intervention: DTIC-monotherapy
Number of subjects: 92
Study 3530176 — intervention group
Group type: COMPARATOR
Intervention: Cross over treatment after progression
Number of subjects: 92
Study 30520854 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 291
Study 30520854 — intervention group
Group type: COMPARATOR
Intervention: No statin treatment
Number of subjects: 291
Study 27494917 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid review by a multidisciplinary antimicrobial stewardship team (intervention arm)
Number of subjects: 160
Study 27494917 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control arm)
Number of subjects: 160
Study 24170750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to reduce regimen distress (RD)
Number of subjects: 392
Study 24170750 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline RD
Number of subjects: 392
Study 24170750 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline medication adherence
Number of subjects: 392
Study 22271776 — intervention group
Group type: EXPERIMENTAL
Intervention: IRT/PAP approach
Number of subjects: 145499
Study 22271776 — intervention group
Group type: EXPERIMENTAL
Intervention: IRT/DNA/sequencing strategy
Number of subjects: 145499
Study 22271776 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strategy (IRT/PAP/DNA/sequencing)
Number of subjects: 145499
Study 20200301 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine once daily
Number of subjects: 973
Study 20200301 — intervention group
Group type: COMPARATOR
Intervention: Insulin detemir twice daily
Number of subjects: 973
Study 19337555 — intervention group
Group type: EXPERIMENTAL
Intervention: CLAs 2.5 g (2 g mixture of cis 9‐trans 11 and trans 10‐cis12 CLAs)
Number of subjects: 87
Study 19337555 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 mg
Number of subjects: 87
Study 19337555 — intervention group
Group type: EXPERIMENTAL
Intervention: CLAs and vitamin E at above doses
Number of subjects: 87
Study 19337555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 15847626 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐based tailored behavioral smoking cessation materials
Number of subjects: 3971
Study 15847626 — intervention group
Group type: COMPARATOR
Intervention: Web‐based non‐tailored materials
Number of subjects: 3971
Study 12218524 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomethiazole edisilate (0.8%), 225 ml loading dose followed by 100 ml/h maintenance during surgery
Number of subjects: 245
Study 12218524 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo)
Number of subjects: 245
Study 10334431 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg i.v. verapamil
Number of subjects: 19
Study 10334431 — intervention group
Group type: COMPARATOR
Intervention: 0.5 N saline
Number of subjects: 19
Study 8961125 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide treatment
Number of subjects: 173
Study 8961125 — intervention group
Group type: COMPARATOR
Intervention: Control group (untested)
Number of subjects: 173
Study 8961125 — intervention group
Group type: COMPARATOR
Intervention: Refusers (offered testing but did not consent)
Number of subjects: 173
Study 8961125 — intervention group
Group type: EXPERIMENTAL
Intervention: Tested group (combined with refusers)
Number of subjects: 173
Study 1957127 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b treatment (3 million units thrice weekly)
Number of subjects: 30
Study 1957127 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b treatment (6 million units thrice weekly for at least 8 weeks)
Number of subjects: 30
Study 1957127 — intervention group
Group type: COMPARATOR
Intervention: Biochemical relapse in responders
Number of subjects: 30
Study 1957127 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological assessment
Number of subjects: 30
Study 1957127 — intervention group
Group type: COMPARATOR
Intervention: Comparison of responders and non-responders
Number of subjects: 30
Study 7011348 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiamenidine (3 mg daily)
Number of subjects: 4
Study 7011348 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (450 micrograms daily)
Number of subjects: 4
Study 7011348 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of Tiamenidine
Number of subjects: 4
Study 7011348 — intervention group
Group type: COMPARATOR
Intervention: Withdrawal of Clonidine
Number of subjects: 4
Study 30939114 — intervention group
Group type: EXPERIMENTAL
Intervention: Athletes
Number of subjects: 583
Study 30939114 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 583
Study 27875802 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 126
Study 27875802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 25414152 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for mild GDM
Number of subjects: 500
Study 25414152 — intervention group
Group type: COMPARATOR
Intervention: No treatment for mild GDM (Control)
Number of subjects: 500
Study 23661035 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectations regarding treatment
Number of subjects: 77
Study 23661035 — intervention group
Group type: EXPERIMENTAL
Intervention: Past experience with treatment
Number of subjects: 77
Study 21122908 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step self-etch adhesive with selective etching of enamel
Number of subjects: 28
Study 21122908 — intervention group
Group type: COMPARATOR
Intervention: Control group (Bond Force adhesive without selective etching)
Number of subjects: 28
Study 18989348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruboxistaurin 32 mg/day
Number of subjects: 506
Study 18989348 — intervention group
Group type: COMPARATOR
Intervention: Moderate visual loss (MVL)
Number of subjects: 506
Study 17972425 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (ACE‐I + BB + ARA or ARB)
Number of subjects: 0
Study 17972425 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (ACE‐I + BB + ARA + ARB)
Number of subjects: 0
Study 17972425 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE‐I and BB combined with diuretics and often with digoxin
Number of subjects: 0
Study 15118203 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice group
Number of subjects: 0
Study 15118203 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked practice group
Number of subjects: 0
Study 15118203 — intervention group
Group type: COMPARATOR
Intervention: Single-task control group
Number of subjects: 0
Study 15118203 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12530553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (3.5 g EPA and 2.4 g DHA per day, each as the ethyl ester)
Number of subjects: 20
Study 12530553 — intervention group
Group type: COMPARATOR
Intervention: Evening primrose oil capsules (no detectable EPA or DHA)
Number of subjects: 20
Study 10326538 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine plus zidovudine
Number of subjects: 28
Study 10326538 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine plus stavudine
Number of subjects: 28
Study 10326538 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine
Number of subjects: 28
Study 10326538 — intervention group
Group type: EXPERIMENTAL
Intervention: stavudine
Number of subjects: 28
Study 10326538 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine
Number of subjects: 28
Study 7622984 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel motion preference after 1 min delay
Number of subjects: 194
Study 7622984 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar motion preference after 1 month delay
Number of subjects: 194
Study 7622984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate retention intervals (1 day, 2 weeks)
Number of subjects: 194
Study 7622984 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarity preference after 3-month interval
Number of subjects: 194
Study 2654576 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counselling by occupational health professionals
Number of subjects: 2489
Study 2654576 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2489
Study 1259046 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 8
Study 1259046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30620727 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (PTH 1–34)
Number of subjects: 54
Study 30620727 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 54